Aptar and Aceso Therapeutics Collaborate to Advance Inhaled ASO Therapy for Cystic Fibrosis

Shots: Aptar Pharma and Aceso Therapeutics have entered into a collaboration to advance ACT-101, an antisense oligonucleotide (ASO) candidate designed to target underlying disease mechanisms of cystic fibrosis (CF) Aptar Pharma’s specialist inhalation development services business; Nanopharm will lead formulation development and device assessment activities to support clinical development of ACT-101 The collaboration combines Nanopharm’s…

ByPrince GiriSeptember 8, 2026

NEWS

Cairn Surgical Reports the FDA De Novo 510(k) Submission for BCL System to Improve Accuracy of Lumpectomy

Shots: The US FDA has received a De Novo 510(k) application for the Breast Cancer Locator (BCL) System to improve the accuracy of breast-conserving surgery (lumpectomy) Cairn Surgical completed its US pivotal trial of the system, with data to be presented at the ASBrS’26 & incl. in the FDA filing, along with earlier data, published…

ByRidhi RastogiMarch 12, 2026

Aptar and Aceso Therapeutics Collaborate to Advance Inhaled ASO Therapy for Cystic Fibrosis

Cairn Surgical Reports the FDA De Novo 510(k) Submission for BCL System to Improve Accuracy of Lumpectomy

Contact US

FOLLOW US